The Global Cancer Immunotherapy Market was USD 36.8 billion in 2016 which is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023. The respective statistics of deaths occurring due to lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer were recorded to be found as 16,90,000, 788,000, 774,000, 754,000, and 571,000 respectively, in 2015

According to CDC, more than 1.5 million people are diagnosed with cancer every year in the U.S., and more than 5 lakhs people are not able to survive. Reports show that 50 % of the total deaths could be prevented through making a healthy choice. Smoking is the leading cause of lung cancer, which is responsible for 90 % of the total deaths in men and 80% in women.

Top Players Business Overview:

Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc. are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Cancer Immunotherapy Market.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/567 .

Cancer Immunotherapy Global Market – Segments:

Global Cancer Immunotherapy Market is segmented in to 3 Key dynamics for an easy grasp and enhanced understanding.

Segmentation By Therapy: Comprises - Monoclonal Antibodies (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, & Bispecific Monoclonal Antibodies), Cytokines (Interferon, Interleukins), Adoptive Cell Transfer and other.

Segmentation By Application: Comprises - Lung Cancer, Liver Cancer, Childhood Cancer, Colorectal Cancer, Stomach Cancer, Lung Cancer and other

Segmentation By End User: Comprises - Hospitals, Clinics & others

Segmentation By Regions: Comprises Geographical regions - North America, Europe, APAC and Rest of the World.

International Cancer Immunotherapy Market Regional Analysis:

North America and Europe account for the largest share of the global cancer immunotherapy market owing to better healthcare, higher income and healthcare spending, and large public healthcare expenditure which accounts for 16 % of GDP.

Asia Pacific is expected to be the fastest growing market due to the presence of rapidly developing healthcare technology, shift of incidence of cancer to the developing economies, huge patient population, and increasing healthcare expenditure. Asia Pacific is anticipated to be led by India, Japan and China.

The Middle East and Africa possess the least market, although, increasing occurrence of cancer owing to rise in risk factors such as smoking, change in lifestyle, and alcoholism are driving the cancer immunotherapy market shift in favour of this region. The Middle East and Africa market is led by the Gulf economies of Saudi Arabia, UAE, Kuwait and Qatar.

Ask Questions to Experts @ https://www.marketresearchfuture.com/enquiry/567 .

About Us:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028         

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]